SCHEMBL3518800

SCHEMBL3518800

CCC1Oc2ccccc2C(=O)C1(C)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
DNMT3B Q9UBC3 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
AR P10275 1/20 0.35
CYP19A1 P11511 1/20 0.35
MAOB P27338 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
MAPT P10636 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25201529 0.78 DNMT3B (0.52) DNMT3BKDM4EADORA3ARCYP19A1
SCHEMBL11377418 0.69 DRD3 (0.33) ALDH1A1DNMT3BKDM4EADORA3AR
SCHEMBL11385200 0.69 KMT2A (0.33) ALDH1A1DNMT3BKDM4EADORA3AR
Hydrochloric Acid SCHEMBL11091455 0.68 MEN1 (0.46) ALDH1A1DNMT3BKDM4EARCYP19A1
SCHEMBL31217604 0.66 MEN1 (0.44) ALDH1A1KDM4EADORA3ARCYP19A1
SCHEMBL10353380 0.65 DNMT3B (0.40) ALDH1A1DNMT3BKDM4EADORA3AR
SCHEMBL11384224 0.64 KMT2A (0.38) ALDH1A1KMT2AMEN1MAPTTDP1
SCHEMBL26091520 0.64 STK17B (0.51) ALDH1A1KDM4EADORA3ARCYP19A1
SCHEMBL27978153 0.64 DNMT3B (0.42) ALDH1A1DNMT3BKDM4EADORA3AR
SCHEMBL3517906 0.64 PKM (0.41) ALDH1A1KDM4ECYP19A1MAOBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7667053-B2 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders MERCK & CO., INC. (US) 2010-02-23 US disclosed
EP-1499306-A4 BICYCLIC AMIDES MERCK & CO INC (US) 2007-03-28 EP disclosed
US-20050203112-A1 Bicyclic amides MERCK SHARP & DOHME CORP. 2005-09-15 US disclosed
EP-1499306-A2 BICYCLIC AMIDES Merck & Co., Inc. (US) 2005-01-26 EP disclosed
WO-2003086288-A2 BICYCLIC AMIDES MERCK & CO., INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203112-A1 Bicyclic amides CNR1, CNR2, FAAH ALDH1A1 3047/4885DNMT3B 3625/4885KDM4E 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.